CRISPR Therapeutics
CRSP
CRSP
395 hedge funds and large institutions have $2.45B invested in CRISPR Therapeutics in 2022 Q4 according to their latest regulatory filings, with 56 funds opening new positions, 117 increasing their positions, 120 reducing their positions, and 87 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
395
Holders Change
-39
Holders Change %
-8.99%
% of All Funds
6.37%
Holding in Top 10
3
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-62.5%
% of All Funds
0.05%
New
56
Increased
117
Reduced
120
Closed
87
Calls
$109M
Puts
$86.2M
Net Calls
+$23.2M
Net Calls Change
+$12.7M
Top Buyers
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
$122M |
| 2 |
State Street
Boston,
Massachusetts
|
$84.6M |
| 3 |
BlackRock
New York
|
$107M |
| 4 |
Barclays
London,
United Kingdom
|
$15.8M |
| 5 |
PI
PEAK6 Investments
Chicago,
Illinois
|
$11.1M |
